These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Five- to eight-year follow-up of patients with the Hancock cardiac bioprosthesis.
    Author: Gallo I, Ruiz B, Duran CM.
    Journal: J Thorac Cardiovasc Surg; 1983 Dec; 86(6):897-902. PubMed ID: 6645592.
    Abstract:
    All patients undergoing a heart valve replacement with a glutaraldehyde-preserved Hancock xenograft from June, 1974, through June, 1977, were reviewed. This analysis included 403 patients: 202 having mitral valve replacement (MVR), 131 having aortic valve replacement (AVR), and 70 having mitral and aortic valve replacement (M/AVR). The hospital mortality was 9.9% (40/403): 10.8% (22/202) for MVR, 4.5% (6/131) for AVR, and 17.1% (12/70) for M/AVR. Of 363 patients discharged from the hospital, six were lost to follow-up at 24 and 37 months and they are excluded from the figures. There were 41 late deaths, which represents an incidence of 1.47% per patient-year for MVR (16/177), 1.95% per patient-year for AVR (14/122), and 3.35% per patient-year for the M/AVR (11/58). There were 37 thromboembolic events in 32 patients. This represents a linearized incidence of 1.93%, 0.97%, and 2.74% per patient-year for MVR, AVR, and M/AVR, respectively. None of the accidents was fatal, and four of the 32 patients were on a regimen of controlled anticoagulation at the time of embolism. Primary tissue failure was observed in 34 patients (231 MVR, eight AVR, and five MAVR). The probability of being free from primary tissue failure at 8 years is 85.3% +/- 3.7% for MVR, 85% +/- 11.6% for AVR, and 81% +/- 8.9% for M/AVR. These current results indicate that the Hancock xenograft valve can be considered as a valid alternative in heart valve replacement.
    [Abstract] [Full Text] [Related] [New Search]